NGM·Healthcare·$1.8B·#337 / 520 in Healthcare
NRIX Nurix Therapeutics, Inc.
35HIGH RISK
CATEGORY BREAKDOWN
GROWTH82
QUALITY0
STABILITY57
VALUATION6
GOVERNANCE6
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+54.0%
82
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
12 months
39
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
10.3%
92
< 25% strong
Price / Sales
Market cap relative to trailing revenue
24.4x
6
< 3x strong
Rule of 40
Growth rate plus operating margin
-286
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
1.1%
9
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+35.3%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE NRIX WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when NRIX's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.